Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label phase 2/3 clinical study in Japan
Keishi Kido, Kayo Ibaragi, Mitsuyoshi Tanishima, Yosuke Muramoto, Shun Nakayama, Kohei Ata, Kenshi Hayashida, Hideki Nakamura, Yasuhiko Shinmura, Yoshiaki Oda, Masafumi Endo, Kengo Sonoda, Yuji Sasagawa, Yasuhiro Iwama, Kohji Ueda, Takayuki Matsumoto
doi: https://doi.org/10.1101/2022.10.27.22281603
Keishi Kido
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Kayo Ibaragi
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Mitsuyoshi Tanishima
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Yosuke Muramoto
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Shun Nakayama
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Kohei Ata
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Kenshi Hayashida
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Hideki Nakamura
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Yasuhiko Shinmura
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Yoshiaki Oda
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Masafumi Endo
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Kengo Sonoda
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
Yuji Sasagawa
2Meiji Seika Pharma Co., Ltd., Tokyo, Japan
Yasuhiro Iwama
2Meiji Seika Pharma Co., Ltd., Tokyo, Japan
Kohji Ueda
3Professor emeritus, Kyushu University, Fukuoka, Japan
Takayuki Matsumoto
1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted November 02, 2022.
Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label phase 2/3 clinical study in Japan
Keishi Kido, Kayo Ibaragi, Mitsuyoshi Tanishima, Yosuke Muramoto, Shun Nakayama, Kohei Ata, Kenshi Hayashida, Hideki Nakamura, Yasuhiko Shinmura, Yoshiaki Oda, Masafumi Endo, Kengo Sonoda, Yuji Sasagawa, Yasuhiro Iwama, Kohji Ueda, Takayuki Matsumoto
medRxiv 2022.10.27.22281603; doi: https://doi.org/10.1101/2022.10.27.22281603
Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label phase 2/3 clinical study in Japan
Keishi Kido, Kayo Ibaragi, Mitsuyoshi Tanishima, Yosuke Muramoto, Shun Nakayama, Kohei Ata, Kenshi Hayashida, Hideki Nakamura, Yasuhiko Shinmura, Yoshiaki Oda, Masafumi Endo, Kengo Sonoda, Yuji Sasagawa, Yasuhiro Iwama, Kohji Ueda, Takayuki Matsumoto
medRxiv 2022.10.27.22281603; doi: https://doi.org/10.1101/2022.10.27.22281603
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2659)
- Dermatology (224)
- Emergency Medicine (401)
- Epidemiology (12259)
- Forensic Medicine (10)
- Gastroenterology (765)
- Genetic and Genomic Medicine (4122)
- Geriatric Medicine (387)
- Health Economics (681)
- Health Informatics (2667)
- Health Policy (1007)
- Hematology (364)
- HIV/AIDS (854)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (440)
- Neurology (3904)
- Nursing (210)
- Nutrition (579)
- Oncology (2043)
- Ophthalmology (587)
- Orthopedics (242)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (453)
- Public and Global Health (6546)
- Radiology and Imaging (1407)
- Respiratory Medicine (871)
- Rheumatology (411)
- Sports Medicine (343)
- Surgery (452)
- Toxicology (54)
- Transplantation (186)
- Urology (167)